Beyond Air (XAIR) to Release Earnings on Tuesday

Beyond Air (NASDAQ:XAIRGet Free Report) is expected to be releasing its Q1 2027 results before the market opens on Tuesday, August 11th. Analysts expect Beyond Air to post earnings of ($10.10) per share and revenue of $1.8640 million for the quarter. Individuals may visit the the company’s upcoming Q1 2027 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:00 AM ET.

Beyond Air (NASDAQ:XAIRGet Free Report) last posted its earnings results on Friday, June 26th. The company reported ($15.40) EPS for the quarter, missing analysts’ consensus estimates of ($11.33) by ($4.07). The firm had revenue of $1.91 million for the quarter, compared to analysts’ expectations of $2.30 million. Beyond Air had a negative return on equity of 350.00% and a negative net margin of 432.99%.

Beyond Air Price Performance

Beyond Air stock traded up $0.16 during trading hours on Tuesday, hitting $6.49. The stock had a trading volume of 32,236 shares, compared to its average volume of 169,593. Beyond Air has a 1-year low of $5.02 and a 1-year high of $95.60. The stock has a market capitalization of $4.67 million, a price-to-earnings ratio of -0.07 and a beta of 0.23. The stock’s fifty day moving average is $7.66 and its two-hundred day moving average is $13.92. The company has a debt-to-equity ratio of 3.48, a current ratio of 3.80 and a quick ratio of 3.59.

Insider Activity at Beyond Air

In other Beyond Air news, CEO Robert Scott Goodman bought 34,722 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The stock was purchased at an average cost of $5.76 per share, for a total transaction of $199,998.72. Following the completion of the purchase, the chief executive officer owned 34,822 shares of the company’s stock, valued at $200,574.72. This trade represents a 34,722.00% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 9.99% of the stock is currently owned by corporate insiders.

Institutional Trading of Beyond Air

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Alyeska Investment Group L.P. acquired a new stake in Beyond Air during the 3rd quarter worth approximately $1,753,000. Osaic Holdings Inc. raised its stake in shares of Beyond Air by 26.4% in the 2nd quarter. Osaic Holdings Inc. now owns 162,560 shares of the company’s stock valued at $29,000 after acquiring an additional 34,000 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Beyond Air by 57.5% during the 4th quarter. Geode Capital Management LLC now owns 67,678 shares of the company’s stock valued at $49,000 after acquiring an additional 24,695 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in Beyond Air during the 3rd quarter worth $48,000. Hedge funds and other institutional investors own 31.50% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Beyond Air in a report on Tuesday, July 21st. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $200.00.

View Our Latest Stock Analysis on XAIR

Beyond Air Company Profile

(Get Free Report)

Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.

The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.

Featured Stories

Earnings History for Beyond Air (NASDAQ:XAIR)

Receive News & Ratings for Beyond Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyond Air and related companies with MarketBeat.com's FREE daily email newsletter.